09.07.2013 | 130709_Press_release_Epigenomics_AG_ADR
- Epigenomics ADRs can be traded on US over-the-counter (OTC) market effective as of July 9, 2013
- ADR ticker symbol EPGNY
- 1 ADR represents 5 ordinary company shares
Berlin, Germany, and U.S.A. – Epigenomics AG (Frankfurt Prime Standard: ECX), the German-American cancer molecular diagnostics company, today announced that the Company has established a Level 1 ADR program in the U.S.A. BNY Mellon has been appointed as the depositary bank for the ADR program. ADRs of Epigenomics are US dollar negotiable certificates representing ordinary shares of the Company at a ratio of five ordinary shares to one Epigenomics ADR. Epigenomics ADRs can be traded on the US OTC market effective as of July 9, 2013 under the ticker symbol EPGNY. Ordinary Epigenomics shares are traded in Frankfurt Prime Standard, Germany, under the ticker symbol ECX.
“In the light of our focused US strategy and the upcoming decision about the approval of our blood-based test for the early detection of colorectal cancer, Epi proColon®, we experience growing interest of US investors,” explained Dr. Thomas Taapken, CEO/CFO of Epigenomics AG. “We established the ADR program as a service to offer those investors an easy way to buy our shares and to consequently broaden the shareholder base in our core market.”
– Ends –
Contact Epigenomics AG
For US press inquiries:
9700 Great Seneca Highway Rockville
About Level 1 American Depositary Receipt (ADR) Program
The Level 1 ADR program allows US investors to trade shares in the form of securities from companies that are not listed in the US. ADRs represent ordinary shares of a company at a certain ratio. They are traded on the US over-the-counter (OTC) market and are issued according to the demand (Unsponsored) or in cooperation with one designated depositary bank that acts as the transfer agent (Sponsored). The price generally tracks the price of the foreign security in its home market, adjusted for the ratio of ADRs to foreign company shares.
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies and testing laboratories. Epigenomics is an international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.